Breaking News on Global Pharmaceutical Technology & Manufacturing

Find other oral forms for tablet-hating patients, drugmakers told

02-Sep-2014 - Pharma firms must provide imaginative solid dosage alternatives to tablets and capsules, says researching claiming more than half of patients have problems swallowing traditional pills.

CFDA approves BTG bead delivery device for liver cancer

29-Aug-2014 - BTG has received approval from the China FDA for a liver cancer treatment which uses its hydrogel product DC Beads.

GSK and Immunovaccine: delivery techs promise to deliver Ebola vaccine

29-Aug-2014 - A candidate Ebola vaccine that uses Immunovaccine's formulation technology has stopped cynomolgus monkeys from catching the disease in a preclinical study.

GSK welcomes US OK for Arnuity in light of declining Advair sales

21-Aug-2014 - US FDA approval of the inhaled corticosteroid (ICS) asthma drug Arnuity will help offset declining sales of the off-patent bestseller Advair, says GlaxoSmithKline.

US FDA approves first needle-free flu vaccine delivery system

19-Aug-2014 - For the first time ever, the US FDA has approved a needle-free injection system to deliver the seasonal flu vaccine.

Prometheon goes crowdfunding to develop patch delivery tech

12-Aug-2014 - Pricks are a problem for the drug industry according to Prometheon Pharma, which has launched a crowdfunding campaign to help it develop a needle-free alternative delivery tech.

Roche's oral octreotide pull-out no risk for Capsugel, says Chiasma

12-Aug-2014 - Chiasma says a scale-up manufacturing agreement with Capsugel will be unaffected despite Roche pulling out of a commercialisation contract for its oral peptide drug octreotide acetate.

Sanofi in $150m deal to commercialise Mannkind's inhaled insulin

11-Aug-2014 - Mannkind has partnered Sanofi for the marketing and commercialisation of its inhaled insulin drug Afrezza, recently approved by the US FDA.

Oncologist: Delivery is key for improving pancreatic cancer treatment

06-Aug-2014 - Pancreatic cancer is notoriously difficult to treat.  One problem is drug delivery, because pancreatic cells can cluster in a nest of scar-like tissue. 

Actavis welcomes AZ in boosting its LAMA/LABA

06-Aug-2014 - Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

Roche re-enters gene silencing space with $250m LNA acquisition

05-Aug-2014 - Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its ‘antisense’ Locked Nucleic Acid (LNA) platform.

AstraZeneca coughs up $875m for Almirall to support asthma/COPD pipeline

04-Aug-2014 - AstraZeneca has bolstered its respiratory portfolio and added new bronchodilator technologies through the $875m (€650m) acquisition of Almirall.

Harvard develops new nanoparticle as drug delivery device

31-Jul-2014 - A group of researchers at Harvard Medical School has developed a strongly cationic nanoparticle that physically absorbs proteins to form a new type of drug-carrier complex in aqueous solution. 

Anti-addiction film resilient to generics, says Reckitt Benckiser

29-Jul-2014 - Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business.

Ben Venue assets will bolster sterile injectables network, says Hikma

28-Jul-2014 - Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.

GSK's declining Advair sales to be propped by respiratory portfolio

24-Jul-2014 - GlaxoSmithKline has issued upbeat guidance despite a 12% fall in sales of its blockbuster asthma and COPD drug Advair, as new products enter the respiratory drug market.

MonosolRx finds new licensee for oral film delivered ondansetron

23-Jul-2014 - MonosolRx has found a new US licensee for its oral film ondansetron product, Zuplenz, signing up Galena BioPharma nearly four years after previous partner Strativa handed the drug back.


Sterile injectables M&A could indicate return to in-house production

22-Jul-2014 - Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.

Allergan further fends off Valeant with 1,500 job cuts, M&A projections

22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as it continues to avoid a $54bn hostile takeover bid from Valeant Pharmaceuticals.

Pfizer and Sun open wallets in latest sterile injectable deals

17-Jul-2014 - Pfizer and Sun Pharmaceutical Industries have boosted their sterile injectables businesses through the respective acquisitions of InnoPharma and the CMO Pharmalucence.


Hovione and Merrion team on solubility solutions

16-Jul-2014 - Hovione has teamed up with delivery tech developer Merrion Pharmaceuticals to provide developers of BCS class III and IV drugs with more solubility enhancement options.

Priority Review for Purdue’s anti-abuse hydrocodone

09-Jul-2014 - The US FDA has granted Priority Review Designation to Purdue Pharma’s hydrocodone bitartrate tablet which has abuse-deterrent technology.

Zogenix adds abuse deterrents to Zohydro painkiller

03-Jul-2014 - Zogenix has modified its much-debated painkiller Zohydro with abuse-deterrent formulations.

Afrezza approval: US FDA validation for Mannkind's drug and delivery tech

01-Jul-2014 - The US FDA approved Afrezza last weekend after deeming that the inhaled insulin drug and the dry powder delivery technology used to get it deep into the lungs is effective.

Oasmia's vitamin A excipient tech attract global pharma collaborator

26-Jun-2014 - Oasmia Pharmaceutical AB has teamed up with a “global pharmaceutical company” interested in its vitamin A-based nanoparticle formulation tech in a move that expands its business model to drug development partnering.


SCM's woes part of UK-wide aseptic slowdown, says ex-owner

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend...

Boehringer aims to cut German costs 15% as H1 sales fall

Boehringer Ingelheim aims to cut German costs 15% as revenues drop

German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer...

WHO: Data from use of unapproved Ebola drugs should be shared

WHO: Data from use of unapproved Ebola drugs should be shared

Efficacy and safety data from use of unapproved Ebola virus treatments should be shared according to an...

THC may reduce tumor size? mouse study investigates

THC may reduce tumor size? mouse study investigates

A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in...

India’s CDSCO outlines procedures for state manufacturer inspections

India’s CDSCO outlines procedures for state inspections of manufacturers

In order to ensure uniformity on the state and federal levels, India’s CDSCO (Central Drugs Standard Control...

Roche re-enters RNAi space with $250m Santaris acquisition

Roche re-enters gene silencing space with $250m LNA acquisition

Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its...

Key Industry Events


Access all events listing

Our events, Events from partners...